Canadian researchers should be aware the there is a motion before the Parliamentary Standing Committee on Science and Research to force Tricouncils to hand over disaggregated peer review data on all applications:
Applicant names, profiles, demographics
Reviewers names, profiles, comments, and scores

Dr. Moorthy reviewing the WHO global action plan for clinical trial ecosystem strengthening at the 4th Annual ACT meeting in Cape Breton, NS. We are making progress in Canada but lots of work to do!
@cvcualberta.bsky.social @csnscn.bsky.social @ualberta.bsky.social

What’s your treatment for idiopathic pericarditis in PD?
NSAIDs will cause loss of RRF and risk of UGIB. Colchicine at even low doses=diarrhea (and myopathy/cytopenias). Prednisone or try colchicine 0.3-0.6mg po daily to see if tolerated? Defer to cardiology? @askrenal.bsky.social #askrenal

In patients receiving #maintenancedialysis, there is substantial variability across the 4 steps required to receive a #kidneytransplant with the rate of referral varying almost 8-fold across Ontario’s Regional Renal Programs
@lhsccanada.bsky.social @csnscn.bsky.social

doi.org/10.1177/2054...

Design of the international #ACHIEVE trial comparing spironolactone to placebo in over 2500 people receiving #dialysis for #kidneyfailure.
@csnscn.bsky.social @cjkhd.bsky.social

doi.org/10.1177/2054...

It was a pleasure to work with Dr. Adeera Levin on this JCI editorial re: the impact of gender affirming hormone therapy on blood/urine biomarkers and renal plasma flow/iohexol plasma GFR. Provides new insights to sex based differences in kidney function.

pubmed.ncbi.nlm.nih.gov/40309772/

Really enjoyed writing this editorial on the PK of Sativex in healthy controls and CKD from Denmark with Brendan Smyth from Sydney:

pubmed.ncbi.nlm.nih.gov/40303213/

Stay tuned for our PK study of oral THC/CBD (MPL-001) in CKD/dialysis @lastwalsh.bsky.social @csnscn.bsky.social @cntn

65 year old male DM2 HFrEF on RAAS-i and SGLT2-i starts incremental PD with eGFR 7 for volume and uremic symptoms. A1C above target and RRF 1L. Do you keep them on SGLT2-i? You don’t have the luxury to randomize in RENAL-LIFECYCLE. @askrenal.bsky.social

Celebrating Kevin’s successful MSc defense (my 1st graduate student). Watch out for some papers re: SR/MA of screening for MCI/dementia in kidney disease and the representativeness of the elderly in dialysis RCTs. Thanks for Drs. Klarenbach, Thompson and Camicioli (committee)
#UofA #AbSPORU